Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.

Journal of cancer research and clinical oncology - 1 Feb 2013

Messner Isabelle, Cadeddu Giuseppe, Huckenbeck Wolfgang, Knowles Helen J, Gabbert Helmut E, Baldus Stephan E, Schaefer Karl-Ludwig

Abstract excerpt

PURPOSE: Targeted therapies using the anti-EGFR antibodies panitumumab (Pmab) or cetuximab (Cmab) are currently restricted to patients with metastatic colorectal adenocarcinoma whose tumours do not show a mutation in KRAS. However, recent retrospective studies indicated that patients with tumours mutated in codon 13 of KRAS may benefit from treatment with Cmab in contrast to patients with tumours mutated in KRAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Class I Phosphatidylinositol 3-Kinases

Share to Panitumumab

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 23015072
DOI: 10.1007/s00432-012-1319-7

Genes

KRAS
EGFR
BRAF
PTEN

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.PMID 23015072Read ↗

Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.Semantic proximity Read ↗

Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?Semantic proximity Read ↗

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.Semantic proximity Read ↗

Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.Semantic proximity Read ↗

Clinical relevance of KRAS mutations in codon 13: Where are we?Semantic proximity Read ↗

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.Semantic proximity Read ↗

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.Semantic proximity Read ↗

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.Semantic proximity Read ↗

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.Semantic proximity Read ↗

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.Semantic proximity Read ↗

Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12D Inhibitor, in Colorectal Cancer Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.